Elektrofi Stock
HealthTechLooking to sell Elektrofi stock or options?
Elektrofi has developed a drug delivery platform aimed at enhancing subcutaneous administration. Their formulation system efficiently processes a wide range of therapeutic molecules, and their technology is capable of handling large, complex, and delicate proteins, such as monoclonal antibodies, as well as bispecific and fusion proteins. This enables drug manufacturers to create groundbreaking therapies with ease, empowering patients to have control over how they receive and benefit from transformative medicines.
Novo Holdings, Charlotte Angel Fund, Leerink Partners, Eli Lilly and Company, Catalio Capital Management, Flobas Ventures, Paradigm BioCapital, Samsara BioCapital, Woodline Partners, Royalty Pharma, RA Capital Management, BVF Partners, Marshall Wace, Checkpoint Capital, General Catalyst, TPG, SR One Capital Management, Braidwell, Janus Henderson Investors, National Science Foundation, Deep Track Capital, Logos Capital, Kearny Venture Partners.
Our available services for this company
Management Team
Board Members
Elektrofi’s stock FAQs
Elektrofi is currently a private company. This means that the company is not listed on any public exchange and so there is no public market for its stock. However, there may still be ways to monetize Elektrofi stock. Depending on Elektrofi’s policies, you may be able to: (1) find a private buyer in the secondary market to purchase your stock, (2) borrow against your stock, or (3) exchange Elektrofi stock into the Collective Exchange Fund for a limited partnership interest and then borrow non-recourse against your interest to generate immediate cash. This last alternative can be much quicker and net you more after-tax cash than your other options. An exchange into our fund also reduces your risk by diversifying your holdings out of an over-concentrated position.
Collective Liquidity can provide liquidity to shareholders of Elektrofi stock in two ways. First, Elektrofi employees can exchange shares into the Collective Exchange Fund and then borrow non-recourse to generate immediate cash. This can net you more after-tax cash than a stock sale. It also reduces your risk by diversifying your holdings out of an over-concentrated position. In some cases, Collective may also be able to purchase your Elektrofi stock. Note that all transactions in Elektrofi shares are subject to the company’s policies regarding secondary transactions. Schedule a call with a Collective Liquidity representative to learn more about your private market liquidity alternatives.
Elektrofi stock is not listed on any public exchange and so there is no public market for its shares. Therefore, there is no single, centralized price for Elektrofi stock. Typically, shares of private companies like Elektrofi are set with buyers in one off negotiations. Collective Liquidity, however, uses a proprietary algorithm to determine its bids so we almost always have an immediately actionable price for you.
On Aug 2024, Elektrofi is reported to have closed an equity financing in which the investors valued the company at $403M. This valuation is typically calculated by multiplying the per share price of the preferred stock sold in the financing by the number of Elektrofi shares outstanding assuming the conversion of all stock options, warrants, etc.
Tickers are used to identify company’s shares on public markets like the NYSE or Nasdaq. Because Elektrofi is not currently publicly traded, it does not have a ticker symbol.
Elektrofi has not yet conducted an initial public offering (“IPO”) and so remains a private company. Though Elektrofi is a well-known, successful company, there can be no assurance that it will ever go public or be sold. Because of the risk this imposes on Elektrofi shareholders, many investors elect to gain liquidity for at least some of their shares before the IPO. Schedule a call with a Collective Liquidity representative to discuss your private market liquidity alternatives.
